{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:42:51Z","timestamp":1791380571441,"version":"4.3.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Youth Foundation of China","doi-asserted-by":"crossref","award":["81900730"],"award-info":[{"award-number":["81900730"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Empagliflozin, a sodium\u2013glucose co-transporter 2 inhibitor (SGLT2i), has been reported to significantly reduce the risk of heart failure in multiple clinical studies. However, the underlying mechanisms remain elusive. This study aimed to investigate the effect of empagliflozin on branched-chain amino acid (BCAA) metabolism in diabetic cardiomyopathy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirty male 8-week KK Cg-Ay\/J mice were used to study diabetic cardiomyopathy; here, 15 were used as the model group, and the remaining 15 were administered empagliflozin (3.75\u00a0mg\/kg\/day) by gavage daily for 16\u00a0weeks. The control group consisted of fifteen male 8-week C57BL\/6J mice, whose blood glucose and body weight were measured simultaneously with the diabetic mice until 16\u00a0weeks without additional intervention. Echocardiography and histopathology were performed to evaluate cardiac structure and function. Proteomic sequencing and biogenic analysis were performed on mouse hearts. Parallel Reaction Monitoring and western blotting were performed to validate the expression levels of differentially expressed proteins.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The results showed that empagliflozin improved ventricular dilatation and ejection fraction reduction in diabetic hearts, as well as the elevation of myocardial injury biomarkers hs-cTnT and NT-proBNP. At the same time, empagliflozin alleviates myocardial inflammatory infiltration, calcification foci deposition, and fibrosis caused by diabetes. The results of the proteomics assay showed that empagliflozin could improve the metabolism of various substances, especially promoting the BCAA metabolism of diabetic hearts by up-regulating PP2Cm. Furthermore, empagliflozin could affect the mTOR\/p-ULK1 signaling pathway by reducing the concentration of BCAA in diabetic hearts. When mTOR\/p-ULK1 protein was inhibited, ULK1, the autophagy initiation molecule, increased. Moreover, autophagy substrate p62 and autophagy marker LC3B were significantly reduced, indicating that the autophagy activity of diabetes inhibition was reactivated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Empagliflozin may attenuate diabetic cardiomyopathy-related myocardial injury by promoting the catabolism of BCAA and inhibiting mTOR\/p-ULK1 to enhance autophagy. These findings suggest that empagliflozin could be a potential candidate drug against BCAA increase and could be used for other cardiovascular diseases with a metabolic disorder of BCAA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13098-023-01061-6","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T04:01:37Z","timestamp":1683345697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR\/p-ULK1 signaling pathway-mediated autophagy"],"prefix":"10.1186","volume":"15","author":[{"given":"Lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuzhu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruping","family":"Tie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,6]]},"reference":[{"key":"1061_CR1","doi-asserted-by":"publisher","unstructured":"Pop-Busui R, Januzzi JL, Bruemmer D, et al. Heart failure: an underappreciated complication of diabetes. A consensus report of the american diabetes association. Diabetes Care. 2022;45(7):1670\u201390. https:\/\/doi.org\/10.2337\/dci22-0014.","DOI":"10.2337\/dci22-0014"},{"key":"1061_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"NH Cho","year":"2018","unstructured":"Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271\u201381. https:\/\/doi.org\/10.1016\/j.diabres.2018.02.023.","journal-title":"Diabetes Res Clin Pract"},{"key":"1061_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fphar.2020.00042","volume":"11","author":"Y Chen","year":"2020","unstructured":"Chen Y, Hua Y, Li X, et al. Distinct types of cell death and the implication in diabetic cardiomyopathy. Front Pharmacol. 2020;11:42. https:\/\/doi.org\/10.3389\/fphar.2020.00042.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1061_CR4","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","volume":"140","author":"SM Dunlay","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update. Circulation. 2019;140(7):e294\u2013324. https:\/\/doi.org\/10.1161\/CIR.0000000000000691.","journal-title":"Circulation"},{"issue":"4","key":"1061_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","volume":"2","author":"NJ Byrne","year":"2017","unstructured":"Byrne NJ, Parajuli N, Levasseur JL, et al. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl Sci. 2017;2(4):347\u201354. https:\/\/doi.org\/10.1016\/j.jacbts.2017.07.003.","journal-title":"JACC Basic Transl Sci"},{"issue":"22","key":"1061_CR6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"21","key":"1061_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"1","key":"1061_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12263-021-00695-3","volume":"16","author":"W Wang","year":"2021","unstructured":"Wang W, Liu Z, Liu L, et al. Genetic predisposition to impaired metabolism of the branched chain amino acids, dietary intakes, and risk of type 2 diabetes. Genes Nutr. 2021;16(1):20. https:\/\/doi.org\/10.1186\/s12263-021-00695-3.","journal-title":"Genes Nutr"},{"issue":"12","key":"1061_CR9","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.2337\/db13-0570","volume":"62","author":"C Menni","year":"2013","unstructured":"Menni C, Fauman E, Erte I, et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes. 2013;62(12):4270\u20136. https:\/\/doi.org\/10.2337\/db13-0570.","journal-title":"Diabetes"},{"issue":"21","key":"1061_CR10","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1161\/circulationaha.115.020226","volume":"133","author":"H Sun","year":"2016","unstructured":"Sun H, Olson KC, Gao C, et al. Catabolic defect of branched-chain amino acids promotes heart failure. Circulation. 2016;133(21):2038\u201349. https:\/\/doi.org\/10.1161\/circulationaha.115.020226.","journal-title":"Circulation"},{"key":"1061_CR11","doi-asserted-by":"publisher","unstructured":"Gong Q, Zhang R, Wei F, et al. SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db\/db mice. Biomed Pharmacother. 2022;152:113222. https:\/\/doi.org\/10.1016\/j.biopha.2022.113222.","DOI":"10.1016\/j.biopha.2022.113222"},{"key":"1061_CR12","doi-asserted-by":"publisher","unstructured":"Wang L, Yuan D, Zheng J, et al. Chikusetsu saponin IVa attenuates isoprenaline-induced myocardial fibrosis in mice through activation autophagy mediated by AMPK\/mTOR\/ULK1 signaling. Phytomedicine. 2019;58:152764. https:\/\/doi.org\/10.1016\/j.phymed.2018.11.024.","DOI":"10.1016\/j.phymed.2018.11.024"},{"issue":"21","key":"1061_CR13","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.26355\/eurrev_201811_16291","volume":"22","author":"R Liu","year":"2018","unstructured":"Liu R, Zhang HB, Yang J, et al. Curcumin alleviates isoproterenol-induced cardiac hypertrophy and fibrosis through inhibition of autophagy and activation of mTOR. Eur Rev Med Pharmacol Sci. 2018;22(21):7500\u20138. https:\/\/doi.org\/10.26355\/eurrev_201811_16291.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1061_CR14","doi-asserted-by":"publisher","unstructured":"Li H, Ye D, Xie W, et al. Defect of branched-chain amino acid metabolism promotes the development of Alzheimer's disease by targeting the mTOR signaling. Biosci Rep. 2018;38(4):1 https:\/\/doi.org\/10.1042\/BSR20180127.","DOI":"10.1042\/BSR20180127"},{"issue":"1","key":"1061_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00125-017-4390-4","volume":"61","author":"G Jia","year":"2018","unstructured":"Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2018;61(1):21\u20138. https:\/\/doi.org\/10.1007\/s00125-017-4390-4.","journal-title":"Diabetologia"},{"issue":"6","key":"1061_CR16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1042\/ebc20170021","volume":"61","author":"M Zachari","year":"2017","unstructured":"Zachari M, Ganley IG. The mammalian ULK1 complex and autophagy initiation. Essays Biochem. 2017;61(6):585\u201396. https:\/\/doi.org\/10.1042\/ebc20170021.","journal-title":"Essays Biochem"},{"issue":"12","key":"1061_CR17","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/s2213-8587(22)00308-4","volume":"10","author":"SE Inzucchi","year":"2022","unstructured":"Inzucchi SE, Claggett BL, Vaduganathan M, et al. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2022;10(12):869\u201381. https:\/\/doi.org\/10.1016\/s2213-8587(22)00308-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1061_CR18","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41569-020-00455-7","volume":"17","author":"GB Lim","year":"2020","unstructured":"Lim GB. Empagliflozin improves outcomes in HFrEF regardless of diabetic status. Nat Rev Cardiol. 2020;17(11):681. https:\/\/doi.org\/10.1038\/s41569-020-00455-7.","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"1061_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jchf.2021.05.019","volume":"9","author":"M Packer","year":"2021","unstructured":"Packer M. Differential pathophysiological mechanisms in heart failure with a reduced or preserved ejection fraction in diabetes. JACC Heart Fail. 2021;9(8):535\u201349. https:\/\/doi.org\/10.1016\/j.jchf.2021.05.019.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"1061_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15. https:\/\/doi.org\/10.1186\/s12933-019-0816-2.","journal-title":"Cardiovasc Diabetol"},{"issue":"43","key":"1061_CR21","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1093\/eurheartj\/ehab579","volume":"42","author":"SJ Pocock","year":"2021","unstructured":"Pocock SJ, Ferreira JP, Gregson J, et al. Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. Eur Heart J. 2021;42(43):4455\u201364. https:\/\/doi.org\/10.1093\/eurheartj\/ehab579.","journal-title":"Eur Heart J"},{"issue":"10","key":"1061_CR22","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1002\/ejhf.2607","volume":"24","author":"SJ Pocock","year":"2022","unstructured":"Pocock SJ, Ferreira JP, Packer M, et al. Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur J Heart Fail. 2022;24(10):1869\u201378. https:\/\/doi.org\/10.1002\/ejhf.2607.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"1061_CR23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624\u201338. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311586.","journal-title":"Circ Res"},{"issue":"1","key":"1061_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","volume":"18","author":"HC Lee","year":"2019","unstructured":"Lee HC, Shiou YL, Jhuo SJ, et al. The sodium\u2013glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 2019;18(1):45. https:\/\/doi.org\/10.1186\/s12933-019-0849-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1061_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","volume":"14","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis\/stiffness in nondiabetic heart failure: a multimodality study. JACC Cardiovasc Imaging. 2021;14(2):393\u2013407. https:\/\/doi.org\/10.1016\/j.jcmg.2020.07.042.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"1061_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12933-021-01419-y","volume":"20","author":"PA Chevli","year":"2021","unstructured":"Chevli PA, Freedman BI, Hsu FC, et al. Plasma metabolomic profiling in subclinical atherosclerosis: the Diabetes Heart Study. Cardiovasc Diabetol. 2021;20(1):231. https:\/\/doi.org\/10.1186\/s12933-021-01419-y.","journal-title":"Cardiovasc Diabetol"},{"key":"1061_CR27","doi-asserted-by":"publisher","unstructured":"Tobias D K, Lawler P R, Harada P H, et al. Circulating branched-chain amino acids and incident cardiovascular disease in a prospective cohort of US women. Circgen. 2018;11(4):e002157. https:\/\/doi.org\/10.1161\/circgen.118.002157.","DOI":"10.1161\/circgen.118.002157"},{"issue":"34","key":"1061_CR28","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1093\/eurheartj\/ehz235","volume":"40","author":"I Tzoulaki","year":"2019","unstructured":"Tzoulaki I, Castagn\u00e9 R, Boulang\u00e9 CL, et al. Serum metabolic signatures of coronary and carotid atherosclerosis and subsequent cardiovascular disease. Eur Heart J. 2019;40(34):2883\u201396. https:\/\/doi.org\/10.1093\/eurheartj\/ehz235.","journal-title":"Eur Heart J"},{"issue":"1","key":"1061_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-019-0892-3","volume":"18","author":"GM Uddin","year":"2019","unstructured":"Uddin GM, Zhang L, Shah S, et al. Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure. Cardiovasc Diabetol. 2019;18(1):86. https:\/\/doi.org\/10.1186\/s12933-019-0892-3.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"1061_CR30","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1161\/hypertensionaha.119.13735","volume":"74","author":"JL Flores-Guerrero","year":"2019","unstructured":"Flores-Guerrero JL, Groothof D, Connelly MA, et al. Concentration of branched-chain amino acids Is a strong risk marker for incident hypertension. Hypertension. 2019;74(6):1428\u201335. https:\/\/doi.org\/10.1161\/hypertensionaha.119.13735.","journal-title":"Hypertension"},{"key":"1061_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-physiol-020518-114455","volume":"81","author":"M Neinast","year":"2019","unstructured":"Neinast M, Murashige D, Arany Z. Branched chain amino acids. Annu Rev Physiol. 2019;81:139\u201364. https:\/\/doi.org\/10.1146\/annurev-physiol-020518-114455.","journal-title":"Annu Rev Physiol"},{"issue":"6268","key":"1061_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.aab2674","volume":"351","author":"RL Wolfson","year":"2016","unstructured":"Wolfson RL, Chantranupong L, Saxton RA, et al. Sestrin2 is a leucine sensor for the mTORC1 pathway. Science. 2016;351(6268):43\u20138. https:\/\/doi.org\/10.1126\/science.aab2674.","journal-title":"Science"},{"issue":"3","key":"1061_CR33","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1161\/circresaha.117.311147","volume":"122","author":"S Sciarretta","year":"2018","unstructured":"Sciarretta S, Forte M, Frati G, et al. New insights into the role of mTOR signaling in the cardiovascular system. Circ Res. 2018;122(3):489\u2013505. https:\/\/doi.org\/10.1161\/circresaha.117.311147.","journal-title":"Circ Res"},{"issue":"1","key":"1061_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12933-022-01643-0","volume":"21","author":"H Wang","year":"2022","unstructured":"Wang H, Wang L, Hu F, et al. Neuregulin-4 attenuates diabetic cardiomyopathy by regulating autophagy via the AMPK\/mTOR signalling pathway. Cardiovasc Diabetol. 2022;21(1):205. https:\/\/doi.org\/10.1186\/s12933-022-01643-0.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"1061_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.21037\/atm-20-3768","volume":"8","author":"G Zhao","year":"2020","unstructured":"Zhao G, Zhang X, Wang H, et al. Beta carotene protects H9c2 cardiomyocytes from advanced glycation end product-induced endoplasmic reticulum stress, apoptosis, and autophagy via the PI3K\/Akt\/mTOR signaling pathway. Ann Transl Med. 2020;8(10):647. https:\/\/doi.org\/10.21037\/atm-20-3768.","journal-title":"Ann Transl Med"},{"issue":"2","key":"1061_CR36","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/cvr\/cvab033","volume":"118","author":"S Sciarretta","year":"2022","unstructured":"Sciarretta S, Forte M, Frati G, et al. The complex network of mTOR signalling in the heart. Cardiovasc Res. 2022;118(2):424\u201339. https:\/\/doi.org\/10.1093\/cvr\/cvab033.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"1061_CR37","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.2337\/db19-0991","volume":"69","author":"X Sun","year":"2020","unstructured":"Sun X, Han F, Lu Q, et al. Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice. Diabetes. 2020;69(6):1292\u2013305. https:\/\/doi.org\/10.2337\/db19-0991.","journal-title":"Diabetes"},{"key":"1061_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-physiol-021317-121427","volume":"80","author":"S Sciarretta","year":"2018","unstructured":"Sciarretta S, Maejima Y, Zablocki D, et al. The role of autophagy in the heart. Annu Rev Physiol. 2018;80:1\u201326. https:\/\/doi.org\/10.1146\/annurev-physiol-021317-121427.","journal-title":"Annu Rev Physiol"},{"key":"1061_CR39","doi-asserted-by":"publisher","unstructured":"Lin R, Wu S, Zhu D, et al. Osteopontin induces atrial fibrosis by activating Akt\/GSK-3\u03b2\/\u03b2-catenin pathway and suppressing autophagy. Life Sci. 2020;245:117328. https:\/\/doi.org\/10.1016\/j.lfs.2020.117328.","DOI":"10.1016\/j.lfs.2020.117328"},{"issue":"5","key":"1061_CR40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3978\/j.issn.2223-3652.2015.07.02","volume":"5","author":"S Sciarretta","year":"2015","unstructured":"Sciarretta S, Boppana VS, Umapathi M, et al. Boosting autophagy in the diabetic heart: a translational perspective. Cardiovasc Diagn Ther. 2015;5(5):394\u2013402. https:\/\/doi.org\/10.3978\/j.issn.2223-3652.2015.07.02.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"3","key":"1061_CR41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cell.2008.11.044","volume":"136","author":"P Nicklin","year":"2009","unstructured":"Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136(3):521\u201334. https:\/\/doi.org\/10.1016\/j.cell.2008.11.044.","journal-title":"Cell"},{"key":"1061_CR42","doi-asserted-by":"publisher","unstructured":"Liu C, Ji L, Hu J, et al. Functional amino acids and autophagy: diverse signal transduction and application. Int J Mol Sci., 2021;22(21):1. https:\/\/doi.org\/10.3390\/ijms222111427.","DOI":"10.3390\/ijms222111427"},{"key":"1061_CR43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.freeradbiomed.2017.01.009","volume":"104","author":"O Zhenyukh","year":"2017","unstructured":"Zhenyukh O, Civantos E, Ruiz-Ortega M, et al. High concentration of branched-chain amino acids promotes oxidative stress, inflammation and migration of human peripheral blood mononuclear cells via mTORC1 activation. Free Radic Biol Med. 2017;104:165\u201377. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2017.01.009.","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"1061_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13(2):132\u201341. https:\/\/doi.org\/10.1038\/ncb2152.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1061_CR45","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1038\/s41467-020-16886-2","volume":"11","author":"SM Son","year":"2020","unstructured":"Son SM, Park SJ, Stamatakou E, et al. Leucine regulates autophagy via acetylation of the mTORC1 component raptor. Nat Commun. 2020;11(1):3148. https:\/\/doi.org\/10.1038\/s41467-020-16886-2.","journal-title":"Nat Commun"},{"key":"1061_CR46","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.ijcard.2016.08.307","volume":"223","author":"A Jennings","year":"2016","unstructured":"Jennings A, MacGregor A, Pallister T, et al. Associations between branched chain amino acid intake and biomarkers of adiposity and cardiometabolic health independent of genetic factors: a twin study. Int J Cardiol. 2016;223:992\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2016.08.307.","journal-title":"Int J Cardiol"},{"key":"1061_CR47","doi-asserted-by":"publisher","unstructured":"Chen M, Gao C, Yu J, et al. Therapeutic effect of targeting branched-chain amino acid catabolic flux in pressure-overload induced heart failure. J Am Heart Assoc. 2019;8(11):e011625. https:\/\/doi.org\/10.1161\/jaha.118.011625.","DOI":"10.1161\/jaha.118.011625"},{"key":"1061_CR48","doi-asserted-by":"publisher","unstructured":"Voronova V, Sokolov V, Morias Y, et al. Evaluation of therapeutic strategies targeting BCAA catabolism using a systems pharmacology model. Front Pharmacol, 2022, 13: 993422. doi: https:\/\/doi.org\/10.3389\/fphar.2022.993422","DOI":"10.3389\/fphar.2022.993422"},{"key":"1061_CR49","doi-asserted-by":"publisher","unstructured":"Yang Y, Zhao M, He X, et al. Pyridostigmine protects against diabetic cardiomyopathy by regulating vagal activity, gut microbiota, and branched-chain amino acid catabolism in diabetic mice. Front Pharmacol. 2021;12:647481. https:\/\/doi.org\/10.3389\/fphar.2021.647481.","DOI":"10.3389\/fphar.2021.647481"},{"key":"1061_CR50","doi-asserted-by":"publisher","unstructured":"Lian K, Guo X, Wang Q, et al. PP2Cm overexpression alleviates MI\/R injury mediated by a BCAA catabolism defect and oxidative stress in diabetic mice. Eur J Pharmacol. 2020;866:172796. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172796.","DOI":"10.1016\/j.ejphar.2019.172796"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01061-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-023-01061-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01061-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T04:05:22Z","timestamp":1683345922000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-023-01061-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,6]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1061"],"URL":"https:\/\/doi.org\/10.1186\/s13098-023-01061-6","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,6]]},"assertion":[{"value":"19 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Procedures involving animals and their care were conducted in conformity with the revised guidelines (Animals Act 1986) and were approved by the Experimental Animal Welfare Ethics Committee of PLA General Hospital (Approval No. SQ2021248).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}